Business Wire

Scientist.com and Brain and Spine Institute’s Bioincubator, iPEPS, Launch Biotech Startup Competition for Companies Accelerating CNS Disease Research

Jaa

Scientist.com, the life science industry’s leading online marketplace for outsourced research, and The Brain and Spine Institute incubator, iPEPS-ICM, the first innovation accelerator dedicated to brain diseases in France, are partnering to launch a call for biotech startups developing novel approaches to fighting CNS diseases as part of a pitch competition.

This startup call is aimed at helping young biotech entrepreneurs to fast track the development of their innovative projects in one of the most thriving research and innovation ecosystems in Europe. This competition is open to biotech startups worldwide in existence for less than two years developing a novel therapeutic and/or diagnostic approach with a main focus on central nervous system diseases (neuro-oncology, psychiatry, neurological disorders or preventive health).

“In the field of diseases of the nervous system, the probability that drug candidates reach the market is only 7%, compared with an average of 15%,” stated Julien Elric, iPEPS incubator manager. “This outcome makes it very difficult for young enterprises to establish themselves in biotechnology. This startup competition is here to help young entrepreneurs to develop their innovation in the best environment, with 700 researchers at The Brain and Spine Institute, 25 state-of-the-art platforms, a LivingLab and a FabLab.”

Applications can be submitted from May 28, 2018 through July 16, 2018 at ipeps.icm-institute.org/startupcall. An expert panel of judges will narrow the applicant field to 12 in its initial round of selections in early September. A second round of selections occurring in mid-September will determine the winner and one runner up. The winner will have the opportunity to pitch the project to an audience of investors and experts at an event scheduled for late September.

The grand prize winner receives 6 months free rent at iPEPS’ state-of-the-art facilities located in Paris’ 13th district, including consulting with experts in preclinical/clinical development as well as $10K in research services provided through the Scientist.com marketplace. One runner up will receive 3 months free rent at iPEPS and $6K in research services through the Scientist.com marketplace.

“Neurological disorders affect almost a billion people globally,” commented Dan Kagan, PhD, COO of Scientist.com. “This science-based competition highlights novel approaches to these types of diseases and provides two early-stage companies the opportunity to take the next step in the development of their innovative ideas.”

About Scientist.com

Scientist.com is the world's leading marketplace for outsourced research. The marketplace simplifies the entire research sourcing process, saving time and money and providing access to the latest innovative tools and technologies while maintaining full compliance with an organization’s procurement policies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, VWR and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised more than $33 million from Leerink Transformation Partners, 5AM Ventures, Heritage Provider Network, Bootstrap Ventures and Hollywood producer Jack Giarraputo, among others. Visit scientist.com to learn more.

Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook, Google+ and Instagram.

About The Brain and Spine Institute

Located in the heart of the Pitié-Salpêtrière University Hospital Center, the first neurology hospital in France, The Brain and Spine Institute (ICM) is a strong link between basic research and the clinical world. The Institute consists of over 700 researchers and clinicians, 17 cutting-edge technological platforms and a 1000m² office space intended for incubation of startups. The objective is to produce ambitious research by combining scientific creativity and therapeutic purpose.

Contact information

Media Contact:
Scientist.com
Sean Preci
Director of Communications
+1 858-455-1300, ext. 401
marketing@scientist.com
or
For further information, please contact:
The Brain and Spine Institute
Axelle de Chaillé
axelle.dechaille@icm-institute.org
+33 (0)1.57.27.47.02 / +33 (0)7.63.31.55.96
or
Mathilde Gratiot
mathilde.gratiot@icm-institute.org
+ 33 (0)1.57.27.41.87

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

AbuDhabi Dubai STOB Series 22 Investment Enters into Favorable Tender Offer Agreement with MINDOL HOLDINGS21.9.2018 04:00Tiedote

AbuDhabi Dubai STOB Series 22 Investment Limited Partnership, hereafter AbuDhabi22, and MINDOL HOLDINGS LIMITED, hereafter MINDOL, listed on the Hong Kong-based Coinsuper exchange (https://www.coinsuper.com) have reached an agreement where AbuDhabi22 will acquire the minimum 33.3 percent holding for the MINDOL cryptocurrency (MIN, https://mindol.net) to be issued by MINDOL, via a tender offer (TOB). Implementation of the TOB will serve to strengthen the strategic partnership with MINDOL. Both companies expect that the AbuDhabi22 bid will greatly exceed any bids made via ordinary exchange channels. With a bid offering at a stable price, the TOB method was chosen for its strategic worth. The MINDOL business vision for 2019 sets a target for its cryptocurrency, from among the more than 2,000 types of cryptocurrencies currently available, to have a top-30 market capitalization. As a business that focuses on "the fusion of subculture and blockchain," they will develop an online game that ta

Afton Chemical’s S$380 Million Phase II Expansion of Its Jurong Island Plant is Now Complete20.9.2018 23:30Tiedote

Afton Chemical Corporation, a global leader in the lubricant and fuel additive market, today announced the completion of the Phase II expansion of its Chemical Additive Manufacturing Facility in Jurong Island, Singapore. This milestone was marked by a special visit from Singapore’s Minister for Trade & Industry Mr. Chan Chun Sing, who also made a speech and toured the facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005903/en/ Afton Chemical Corporation – Singapore Chemical Additive Manufacturing Facility Phase II Expansion (Photo: Business Wire) As a wholly owned subsidiary of NewMarket Corporation (NYSE: NEU), Afton has been a leading player in the lubricant and fuel additive marketplace for over 90 years. The company was founded on a Passion for Solutions® and has maintained a focus on customizing commercial and industrial solutions that meet customer needs. Afton begun its Singapore manufacturing operations

IFF Announces Pricing of €1,100,000,000 Senior Notes Offering20.9.2018 23:15Tiedote

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensorial experiences that move the world, today announced that it has priced its public offering of €300,000,000 aggregate principal amount of its 0.500% senior notes due 2021 and €800,000,000 aggregate principal amount of its 1.800% senior notes due 2026. IFF intends to use the net proceeds from the offering to pay a portion of the consideration for the previously announced merger with Frutarom Industries Ltd. and to pay related fees and expenses. IFF anticipates that the offering will close on September 25, 2018, subject to customary closing conditions. The offering is not contingent upon the consummation of the merger. If the closing of the merger has not occurred on or prior to February 7, 2019, or, if prior to such date, the merger agreement with Frutarom is terminated, IFF will be required to redeem all of the notes on the special mandatory redemption date at a redem

Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma20.9.2018 20:21Tiedote

Pierre Fabre today announced that the European Commission (EC) has granted marketing authorisation for the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.1,2 The EC decision is applicable to all 28 European Union (EU) member states plus Liechtenstein, Iceland and Norway. "We are extremely pleased that European patients with advanced BRAF-mutant melanoma will now have the combination of BRAFTOVI and MEKTOVI as a new treatment option”, said Frédéric Duchesne, President & CEO of the Pierre Fabre Pharmaceuticals Division. “All of us at Pierre Fabre are driven to make a real difference for patients. Bringing more than 30 years of oncology experience and our heritage in dermatology to our partnership with Array BioPharma, we have been able to harness our expertise in order to help men and women living with this devastating disease. Today’s

Clothesource Report Shows Retail Sales Aren’t Falling or Moving Online: Management’s Let Itself Get Misguided20.9.2018 20:19Tiedote

According to a new Clothesource report, “The Emperors’ Clothes” retail sales aren’t falling, and they’re not leaving physical stores. Both the UK’s Office of National Statistics and the US Bureau of the Census report higher retail sales than ever – with sales in physical stores still growing every year. Retailers just need to rely on their own customer understanding, recapture their self-confidence, and rediscover their traditional frugality. Among recent front-page stories have been Sears in the US hinting it’s about to go under and profits at Britain’s John Lewis falling 99%. But the well run clothing retailers are prospering. Primark goes from strength to strength: the biggest clothing specialists on either side of the Atlantic (Inditex and TJX) have just upped their sales and profit forecasts. So it’s not about consumer purchasing: The main problem lies with management, says Clothesource CEO Mike Flanagan in a new report “The Emperors’ Clothes”. They’ve lost touch with their custom

BCW Names Latin America Market Leaders20.9.2018 19:23Tiedote

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced the appointment of market leaders in Latin America who will be responsible for business growth, client satisfaction and talent development. All market leaders report to Francisco Carvalho, President, Latin America, BCW. “BCW has a dominant presence in Latin America, thanks to Burson-Marsteller’s 40-year-history and expansive footprint across the region and Cohn & Wolfe’s strength in Brazil and Mexico,” said Carvalho. “This team has unmatched market knowledge, strong client relationships and deep commitment to talent, all of which is critical for our continued success in the region. Those strengths, together with our industry-leading expertise in delivering digitally driven integrated communications programs, make BCW a powerful partner for our clients.” All of BCW’s Latin America market leaders have been drawn from the legacy Burson-Marsteller organization and had been leading their respective markets, e

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme